- Real-world 12-month data suggest abiraterone is associated with superior QoL vs enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC).
Why this matters
- Findings in line with meta-analyses of 4 randomized studies (COU-AA-301, COU-AA-302, AFFIRM, and PREVAIL).
- Clinicians should consider treatment effects on patient QoL.
- 12-month AQUARiUS observational study of 226 patients with mCRPC received abiraterone or enzalutamide.
- Outcome: patient-reported outcomes evaluated in four 3-month periods.
- Funding: Janssen EMEA.
- Overall treatment duration was 38.3 weeks in the abiraterone group and 38.7 weeks in the enzalutamide group.
- Abiraterone group showed significantly improved 18 of 28 patient-reported outcome (PRO) items vs enzalutamide (P<.05>
- 9 PRO items were statistically significant in favor of abiraterone for ≥3 periods.
- These PROs were linked to cognition, fatigue, appetite loss, and nausea.
- 69% of patients reported ≥1 adverse event with abiraterone and 77% with enzalutamide.
- Abiraterone group reported lower incidence of fatigue (5% vs 15%) and asthenia (10% vs 11%).
- Observational nonrandomized study.